A Horizon Therapeutics exhibit, called ‘Listen to Your Eyes’ in Atlanta last June.Photo: Matt Odom/Associated Press
Drugmaker Horizon Therapeutics PLC is fielding takeover interest, according to people familiar with the matter, as large pharmaceutical companies compete for fast-growing medicines to fuel sales.
A deal for Horizon, which develops medicines for rare and immune diseases, would be big. The company has a market value of almost $18 billion and, with a typical takeover premium, could fetch a price well over $20 billion.
Already a member? Sign In